IHS Chemical Week

People & Business :: M&A

Xellia expands into the US by acquiring manufacturing plant

12:42 PM MDT | July 7, 2014 | Natasha Alperowicz

Xellia Pharmaceuticals (Copenhagen), a world-leading producer of active pharma ingredients (APIs) and finished dosage forms, today announced it has acquired Fresenius Kabi’s (Lake Zurich, IL) dedicated lyophilized (freeze-dried) vial manufacturing facility at Raleigh, NC. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi's US arm. Financial details have not been disclosed.   The manufacturing site is located close to the Research Triangle Park and is Xellia’s first facility in the United States, significantly...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa